Dublin, Aug. 30, 2018 (GLOBE NEWSWIRE) — The “Oligonucleotide Synthesis Market by Offering, by Application, by End User, by Geography – Global Market Size, Share, Development, Growth and Demand Forecast, 2013 – 2023” report has been added to ResearchAndMarkets.com’s offering.
Based on offering, the oligonucleotide synthesis market is classified into synthesized oligonucleotides, reagents and consumables, and equipment. During the historical period, synthesized oligonucleotides held the largest share in the market, accounting for 76.3% in 2017.
Based on application, the oligonucleotide synthesis market is categorized into research, diagnostics, and therapeutics. Of these, the fastest growth in the market during the forecast period is expected from research applications, with a CAGR of 11.1%.
On the basis of end user, the market is categorized into academic research institutes, diagnostic laboratories, pharmaceutical and biotechnology companies, and others. Others primarily include food and beverage companies and forensic laboratories. Academic research institutes are expected to continue holding the largest share in the oligonucleotide synthesis market in the coming years. They accounted for 40.4% share in the market in 2017.
Geographically, North America held the largest share in oligonucleotide synthesis, with 39.1% contribution in 2017. This can be attributed to technological advancements, favorable government regulations, and high incidence of infectious diseases in the region.
During the forecast period, the oligonucleotide synthesis market is projected to witness the fastest growth in APAC, with a CAGR of 11.6%. The market growth in the region can be attributed to improving healthcare infrastructure, increasing need for better health outcomes, and rising prevalence of chronic and infectious diseases.
Rising geriatric population is also driving the growth of the oligonucleotide synthesis market in APAC. According to the UN publication World Population Ageing 2017, more than 962 million people were aged 60 years or above in 2017, globally, which is more than double the number of the people aged 60 years or above in 1980 (382 million). By 2050, this population is expected to double, to reach 2.1 billion.
According to the UN publication, the number of the Japanese aged 80 years or above was 9 million in 2013, and it is expected to reach 17 million by 2050. In addition, 23.2% of Japanese population aged over 60 years in 2000, and it is expected to reach 35% by 2025.
In order to increase their market share, key players of the oligonucleotide synthesis industry are seeking partnerships and acquisitions. For instance, in May 2018, LGC Biosearch Technologies Inc. (LGC) acquired BioAutomation Corporation (BioAutomation), a manufacturer of MerMade oligo synthesis instruments. The acquisition followed LGC’s acquisitions of Biosearch, Prime Synthesis, and LINK Technologies, and is expected to further drive the company’s growth in the oligonucleotide reagent and synthesized oligonucleotide markets.
In March 2018, Thermo Fisher Scientific Inc. (Thermo Fisher), acquired IntegenX Inc., a provider of rapid DNA platforms for use in forensics and law enforcement applications. IntegenX products have significantly enhanced Thermo Fisher’s existing human identification (HID) portfolio and complemented its leading human identification chemistries, and qPCR and capillary electrophoresis systems.
Some of the other key players operating in the oligonucleotide synthesis industry are General Electric Company, Merck KGaA, Eurofins Scientific SE, Integrated DNA Technologies Inc., GeneDesign Inc., Trilink Biotechnologies LLC, and Kaneka Eurogentec S.A.
Key Topics Covered:
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown Of Primary Research Respondents
2.2.1.1 By Region
2.2.1.2 By Industry Participant
2.2.1.3 By Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions For The Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition Of Market Segments
4.1.1 By Offering
4.1.1.1 Synthesized Oligonucleotides
4.1.1.1.1 By Products
4.1.1.1.1.1 Primers
4.1.1.1.1.2 Probes
4.1.1.1.1.3 Large-Scale Synthesis Oligonucleotides
4.1.1.1.1.4 Intermediate-Scale Synthesis Oligonucleotides
4.1.1.1.1.5 Linkers And Adaptors
4.1.1.1.2 By Services
4.1.1.1.2.1 Custom Oligonucleotides
4.1.1.1.2.2 Pre-Designed Oligonucleotides
4.1.1.2 Reagents And Consumables
4.1.1.3 Equipment
4.1.2 By Application
4.1.2.1 Research
4.1.2.1.1 Polymerase Chain Reaction (Pcr)
4.1.2.1.2 Quantitative Polymerase Chain Reaction (Qpcr)
4.1.2.1.3 Sequencing
4.1.2.1.4 Gene Synthesis
4.1.2.1.5 Others
4.1.2.2 Diagnostics
4.1.2.3 Therapeutics
4.1.2.3.1 Rnai
4.1.2.3.2 Nucleic Acid Aptamers
4.1.2.3.3 Dna/Antisense Oligonucleotides
4.1.2.3.4 Immunotherapy Applications
4.1.3 By End User
4.1.3.1 Academic Research Institutes
4.1.3.2 Diagnostic Laboratories
4.1.3.3 Pharmaceutical And Biotechnology Companies
4.1.3.4 Others
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Technological Advancements In Oligonucleotide Synthesis Products
4.2.1.2 Increasing Support From Government Organizations
4.2.1.3 Increasing Research Activities In Synthetic Biology
4.2.1.4 Increasing Burden Of Cancer And Infectious Diseases
4.2.1.5 Impact Analysis Of Drivers On Market Forecast
4.2.2 Restraints
4.2.2.1 Stringent Regulatory Requirements
4.2.2.2 Lack Of Techniques For Large-Scale Synthesis Of Oligonucleotide
4.2.2.3 Impact Analysis Of Restraints On Market Forecast
4.2.3 Opportunities
4.2.3.1 Growing Focus On Personalized Medicine
4.3 Porter’S Five Forces Analysis
4.3.1 Bargaining Power Of Buyers
4.3.2 Bargaining Power Of Suppliers
4.3.3 Intensity Of Rivalry
4.3.4 Threat Of New Entrants
4.3.5 Threat Of Substitutes
Chapter 5. Global Market Size And Forecast
Chapter 6. North America Market Size And Forecast
Chapter 7. Europe Market Size And Forecast
Chapter 8. APAC Market Size And Forecast
Chapter 9. LATAM Market Size And Forecast
Chapter 10. MEA Market Size And Forecast
Chapter 11. Competitive Landscape
11.1 Product Benchmarking Of Key Players
11.2 Global Strategic Developments Of Key Players
Chapter 12. Company Profiles
- Eurofins Scientific SE
- LGC Limited
- Danaher Corporation
- GeneDesign Inc.
- Maravai LifeSciences Inc.
- Kaneka Eurogentec S.A.
- General Electric Company
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Genscript Biotech Corporation
For more information about this report visit https://www.researchandmarkets.com/research/tg3lq4/global?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics
